πŸ‡ΊπŸ‡Έ FDA
Patent

US 8586553

Therapies for cancer using RLIP76

granted A61KA61K2039/505A61K31/713

Quick answer

US patent 8586553 (Therapies for cancer using RLIP76) held by The Board of Regents of the University of Texas System expires Mon Nov 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Nov 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61K31/713, A61K38/1709, A61K39/3955